Measurement of partner compatibility: further validation and refinement of the CQ test

Abstract

The Compatibility Quotient (CQ) was developed to assess the degree of similarity within an established or potential couple across domains likely to be important in determining long-term happiness. Validity was supported by correlations with Locke–Wallace Marital Adjustment scores and norms presented that enabled CQ scores to be arranged on a normal curve similar to that used for IQ (intelligence) ratings. Here we replicate the validity findings with an independent, larger and more representative sample of British couples (N = 204), compare item validities with ratings of perceived importance of the various issues, and consider the claims of five new items for inclusion within the CQ. A revised (Mark 2) CQ questionnaire consisting of 25 revised items is recommended for future use.     

Health expenditure data for policy: Health accounts,national accounts or both?

Compatibility of statistical frameworks and comparability of data are aspects of statistical quality. This paper explores comparability of data from National Accounts (NA) and Care Accounts/health accounts (CA&HA) of the Netherlands. Although based on the same sources, differences result from specificities of each framework, making data adjustments necessary. Data comparison of major aggregates and household spending is a means for verification and for triangulation of sources. Monitoring household spending on health is one of the Sustainable Development Goals. The usability of NA data for household consumption estimates is key to judge plausibility of household spending levels. However, definitions, coverage and valuation in NA and CA&HA should be understood to benefit from the use of NA data for HA. More than in the concepts used the strength of NA is the way NA are usually produced compared with HA. Key is the integrated analysis including supply and demand to verify the comprehensiveness and consistency. It is concluded that SUT data of NA on consumption of human health and social care can be used for judging plausibility of HA household spending estimates, and, in the absence of the latter, NA data can directly be used. The case of the Netherlands shows that policy measures can have a large impact on the validity of using NA for the estimation of household spending.     

医用X射线机电磁兼容测试中的问题及其分析

目的随着科学技术的发展,国内外对电磁兼容的重视度越来越高。在检测工作中发现大多数X射线机电磁兼容不合格,其原因大都是出于厂方在设计产品时没有进行合理的抑制设计。本文旨在总结不合格项目的整改办法。方法本文通过X射线机静电放电、射频电磁场辐射等抗扰度实验项目,重点分析了X射线机的电磁干扰产生机理及传播方式,并提出通用的整改思路及措施。结果在X射线机各部件的电磁兼容项目整改过程中,通常可采用增加外壳屏蔽、加强接地、更换屏蔽线材等措施对产品进行优化,从而加强其抗干扰性。而其中PCB电路板整改难度最大,需在前期研发过程中重点设计。结论本文对医用X射线机电磁兼容测试中出现的问题深入分析后设计了一套X射线机电磁兼容不合格项目的基本整改流程,帮助企业有效解决常见问题,缩短研发周期,降低研发与物料成本,提升产品质量。     

3种人血清白蛋白降解多肽片段的血液相容性研究

目的 研究3种人血清白蛋白降解多肽片段(PF1-123、PF124-298、PF299-585)的血液相容性.方法 分别考察3种多肽片段对新鲜人血的溶血率、对血细胞形态的影响、全血凝固时间以及血浆复钙时间,测试其血液相容性.结果 PF1-123、PF124-298和PF299-585对新鲜人血的溶血率分别为0.52％±0.47％、0.39％±0.33％、0.32％±0.23％,对血细胞形态均无不良影响,说明3种多肽片段均符合医用材料的溶血率要求;3种多肽片段的全血凝固时间曲线以及血浆复钙时间曲线与人血清白蛋白相似,说明其与血液接触后不会激活相关因子而促成凝血.结论 PF1-123、PF124-298和PF299-585具有良好的血液相容性.     

5种输液调配的生脉注射液成品输液稳定性考察

目的：考察生脉注射液用5％葡萄糖注射液（5％GS）、10％葡萄糖注射液（10％GS）、0．9％氯化钠注射液（0．9％NS）、葡萄糖氯化钠注射液（GNS）和乳酸钠林格注射液（SLR）调配后成品输液的稳定性。方法洁净条件下,生脉注射液用上述5种输液调配为成品输液,室温（25℃）8 h 内观察成品输液的性状、pH、不溶性微粒数及 HPLC 法检测五味子醇甲的含量变化。结果5种成品输液的外观、pH 及五味子醇甲含量均无明显变化;用5％GS、10％GS、0．9％NS 和 GNS 调配的成品输液,4 h 内不溶性微粒符合2010年版《中国药典》一部规定,但用 SLR 调配的成品输液不溶性微粒不符合其规定。结论生脉注射液可以用5％GS、10％GS、0．9％NS 或 GNS 调配为成品输液,并在4 h 内使用。     

Risks of leukapheresis and how to manage them—A non-systematic review

Leukapheresis is like any other preparative apheresis, except it isn’t: Leukapheresis typically takes much longer, larger blood volumes are processed and, consequently, larger ACD-A volumes are administered. Blood component donors and leukapheresis subjects are also quite different populations. Allogeneic donors tend to be younger and many are first-time donors, both of which are risk factors for adverse reactions during blood donation. Moreover, more than half of all leukapheresis collections are performed in patients. Here it is the age distribution, including patients at the extremes of age, as well as the underlying disease and co-morbidities which may expose them to higher, or different, risks compared to donors. Both groups thus have good reasons why adverse effects to leukapheresis might be more frequent, more severe, or even different in nature altogether. Compared to other preparative apheresis types like platelet or plasma apheresis, the risks of leukapheresis have been studied less extensively, as it is in comparison a relatively low-frequency intervention. Often leukapheresis remains a domain of hematologists who have a different sense of procedural safety than transfusionists. Furthermore, G-CSF mobilized “stem cell” aphereses by a wide margin outnumber unmobilized aphereses, so that the very strong signal from adverse reactions to G-CSF all but drowns out signals from the apheresis proper. This focused review assesses observations from leukapheresis as well as extrapolation of observations from other forms of preparative apheresis in an attempt to gauge the safety of leukapheresis and identify potential approaches to its further improvement. In short, the overall impression is one of a very satisfactory safety record of leukapheresis, with occasional issues with venous access or vasovagal problems, and frequent, but highly responsive and rarely limiting ACD-A toxicity.     

Physical Compatibility of Sodium Glycerophosphate and Calcium Gluconate in Pediatric Parenteral Nutrition Solutions

Background: The solubility of inorganic calcium and phosphate in parenteral solutions can be complicated in pediatrics due to the dosing of calcium and phosphorus at the saturation point. The purpose of this study was to test the solubility of sodium glycerophosphate (NaGP) with calcium gluconate in pediatric parenteral nutrition (PN) solutions. Methods: Five PN solutions were compounded by adding calcium gluconate at 10, 20, 30, 40, and 50 mEq/L and corresponding concentrations of NaGP at 10, 20, 30, 40, and 50 mmol/L. Each of the 5 solutions was compounded using 1.5% and 4% amino acids, cysteines, and lipids. Compatibility was evaluated by visual inspection (precipitation, haze, and color change). Solutions were evaluated microscopically for any microcrystals and measured by a turbidimeter for changes in turbidity. Solutions were further analyzed using United States Pharmacopeia 788 standards. Six hundred seventy‐one PN solutions were compounded at various concentrations and evaluated for visual stability. Results: Compatibility testing showed no changes in the PN solution in any of the concentrations tested. Microscopically, no microcrystals were detected. The turbidimeter measurements had changes of ≤0.14 nephelometric turbidity units for all test solutions. There were no visual changes in any of the 671 PN solutions. Conclusion: It is recommended that NaGP replace sodium phosphate in PN solutions. This would eliminate the concern of calcium and phosphorus precipitation and the need of any saturation curves.     

经方中麻黄与石膏的配伍规律探析

通过对以麻黄和石膏为主要配伍的经方进行分析,归纳麻黄与石膏的主要配伍规律。认为麻黄与石膏既可相互制约,又可相互为用,通过剂量的调整和方中其他辅助药物的加减变化,二者配伍应用可以实现发汗清热兼顾、以发汗为主和以清热为主等不同治疗目的。